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Abstract 
 
Photodynamic therapy (PDT) is already being used in the treatment 
of many cancers. This review examines its components and the new 
developments in our understanding of its immunological effects as 
well as pre-clinical and clinical studies, which have investigated its 
potential use in the treatment of breast cancer.  
 
KEY WORDS: breast cancer, photodynamic therapy 
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Background  
Breast cancer is the most common cancer to affect women worldwide [1] and over 50,000 
new cases are diagnosed each year in the UK effecting 1 in 8 women [1,2]. Although 
mortality from breast cancer is falling particularly in the developed countries its incidence is 
rising [2-5]. With the advent of breast screening more cancers are diagnosed early and 
therefore often require less extensive surgical treatment when combined with adjuvant 
therapies. The use of novel technologies to treat all stages of breast cancer is desirable 
because they allow greater options to be available for all patients including those who are 
not eligible for standard management. However in order to be successful they need to offer 
additional benefits or less side effects when compared to the standard of care. In this article 
Photodynamic therapy (PDT) is reviewed with regard to the components that make it a 
successful therapy and the new developments in our understanding of its immunological 
effects. New evidence suggests that PDT has the potential to induce immunity against 
recurrence and destruction of metastases distant from the treated sites, with minimal side-
effects, provides additional advantages over existing treatments.  
 
The successful use of PDT as a therapy [23] requires the optimum combination of light of a 
specific wavelength, a light-activated chemical substance known as a photosensitiser and 
molecular oxygen present in the tissue to elicit cell death through oxidative damage [6]. The 
basis of treatment is dependent on uptake of the photosensitiser into malignant tissue 
following systemic or topical administration. Once the optimum tissue concentration is 
achieved, the malignant tissue can then be exposed to low power visible light for a pre-
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determined time for the treatment to be effective (see Fig.1).  In most cases the spectral 
output of the light source is matched to the absorption spectrum of the photosensitiser in 
order to optimize the photosensitiser activation.  The absorption of light by the 
photosensitiser elevates the molecule from its ground state (S0) to an excited electronic 
state (S1) (Fig.2). Subsequently there is rapid transition from the singlet S1 state to a long-
lived triplet T1 excited state. The photosensitiser can then transfer its internal excited state 
energy to an oxygen molecule to generate ‘singlet oxygen’, a powerful cytotoxic oxidizing 
species [7]. Optimum wavelengths for tissue light transmission lie between 600-800nm 
[8,9]. Across this range the major components of living tissue, namely water, haemoglobin 
in blood and protein have low absorption allowing more efficient light transmission through 
tissue (Fig.3). In addition to singlet oxygen generation via energy transfer (the Type 2 
mechanism), a Type 1 mechanism based on electron transfer between the triplet state and 
biomolecules can also operate. This leads to superoxide anion and other reactive oxygen 
(ROS) formation (see fig 2) [10]. ROS such as singlet oxygen, hydroxyl radicals and 
superoxide anions result in oxidative cell damage and can promote apoptosis (programmed 
cell death) or necrosis depending on the intensity of light delivered. Photo-oxidative 
damage is known to occur to key molecules associated with the cell membrane function 
including amino-acid residues and cholesterol as well as intra-cellular structures including 
nucleic acids, which control normal cellular activity and its relative state within the cell 
cycle.  A critical level of damage to these key structures usually triggers a cascade of cellular 
events leading to irreversible cellular damage apoptosis and tissue necrosis [11-18] as its 
primary effect.  
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Photosensitisers 
The ideal characteristics of the photosensitiser include minimal dark toxicity, with rapid 
selective metabolism and/or clearance from healthy tissue, until the optimum tissue 
concentration has been reached in the malignant tissue, with minimal side effects [6].  One 
factor that might facilitate this process is the leaky vasculature present in tumours 
combined with poorer lymphatic drainage. Therefore tumours can preferentially retain a 
larger concentration of the photosensitizer when administered intravenously compared to 
normal tissue. The ideal light dose is one that it can effectively activate the photosensitiser 
causing cell death to the target tissue but not cause damage to healthy tissue. In reality 
however true selectivity in the light dose is not achievable, and it is instead the targeted 
delivery of light to known areas of disease using fibre-optic light guides while avoiding 
healthy tissues, which are also photosensitive, that facilitates effective treatment. New 
clinically used photosensitisers have strong red or near-infrared absorption and a well-
defined composition with simple and stable drug formulation delivered through the 
intravenous route.  
 
The structural characteristics of individual compounds have a significant role in their 
suitability to act as a photosensitiser [19]. Aromatic tetrapyrrolic structures are particularly 
suitable [17,20]. The first generation of commercial photosensitisers,  Haematoporphrin 
derivative (HpD )and its purified version Photofrin, were based on this structure.  
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While showing efficacy as good photosensitisers and preferentially localizing within 
tumours, they exhibited a prolonged photosensitivity due to a long cutaneous retention 
half-life in patients, and poor absorption at longer red wavelengths, limiting their treatment 
use. 
 
A second generation of compounds specifically designed to have minimal side-effects and 
overcome the undesirable qualities of their predecessors is now available which has 
facilitated PDT use in cancer therapy. These are an extensive group of compounds used in a 
wide range of therapeutic applications.  In terms of cancer therapy alone this includes 5-
Aminolaevulinic acid (ALA), which is metabolized to a porphyrin photosensitizer, and 
esterified derivatives of ALA [21,22], i.e. its methyl and hexyl esters. [16,23]. Another family 
of compounds, phthalocyanines, has been investigated for their potential use in cancer 
therapy [24,25,26] as well as tools to improve our understanding of how PDT exerts its 
effect. Since many of the most effective photosensitisers are lipophilic and are taken up 
avidly by cell membranes including organelle membranes, investigation of novel delivery 
systems to overcome poor water solubility of such compounds is being pursued [27,28]. An 
example of this is zinc phthalocyannine, which has been used recently to investigate the 
pathways of cell death in breast cancer cell lines exposed to PDT [29] (Table 1). This 
photosensitiser showed potential as therapeutic agent when delivered through albumin 
nanospheres with good efficacy and no adverse effects in a murine model [30]. 
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Compounds used specifically in breast cancer (Table 1) for the treatment of cutaneous 
metastases include Visudyne™ which contains a benzoporphorin derivative monoacid ring A  
(verteporfin or BPD-MA) [23,31,32], as a liposomal formulation to overcome the poor water 
solubility of the verteporfin photosensitiser. Advantages to using this agent in breast cancer 
therapy include the high tissue penetration at its peak absorption at 690nm, with optimum 
concentration in malignant tissue lasting between 30 to 150 minutes before being 
completely cleared at 48 hours.  
 
Purlytin™ (tin etiopurpurin) , a chlorin photosensitiser  has also been investigated for use in 
the treatment of cutaneous metastases  of breast cancer [33]. Its structure results in a 
stronger absorption of light at the 650-680nm range. Another group of photosensitisers, the 
Texaphyrins have been explored, which are expanded porphyrins with a penta-aza core that 
facilitates strong absorption of light in the 730-770nm range.  Lutex™ (Lutetium texaphyrin) 
has been assessed in the treatment of breast cancer skin lesions  [31]. In clinical trials 
texaphyrins have also been used as radio-sensitizers [11].  
 
Standard chemotheraputic agents such as anthracyclines and anthraquinones have been 
examined with regard to their structural properties to assess their ability to act as 
photosensitisers [34,35]. Specifically Mitoxantrone a type II topoisomerase inhibitor has 
been investigated for their suitability as photosensitisers in order to combine their cytotoxic 
effects with PDT but at a lower dose compared to standard systemic chemotherapy 
treatment therefore incurring fewer side-effects. Additionally this may allow treatment of 
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drug and radiation resistant tumour cells [36,37]. Montazerabadi et al investigated its 
effects as a potential photosensitiser on breast cancer cell lines and their results suggested 
it to be an efficient photosensitiser [36]. However other studies are not as conclusive. 
 
Secret et al in 2013 demonstrated that porous silicon nanoparticles can also be used to 
covalently carry porphyrin related photosensitisers into breast cancer cells to in order to 
improve bioavailability for PDT treatment [38] and albumin based nanopheres and 
liposomes [39] have successfully used for photosensitiser delivery. However this has yet to 
be translated beyond cell line and animal model based studies. One of the difficulties 
identified with the use of nanospheres is that they are less successful at carrying the 
photosensitiser at high doses and retaining them in their active state [40]. The development 
of poly (N-isopropylacrylamide)- PNIPAM microgel for encapsulation of photosensitisers 
may lead to improved efficacy [40,41,42]. 
 
Nanoparticles that are biodegradeable and include PNIPAM microgel, stabilize 
photosensitisers as they are able to provide protection against degradation by enzymes and 
the microenvironment in vivo. Khanal et al in 2014 [40] used PNIPAM to encapsulate, 
methylene blue, which was used as a photosensitiser against a breast cancer cell line 
treated with PDT. Their results confirmed improved efficacy could be achieved using this 
technique. 
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Other novel photosensitisers that are in development for PDT, include bacteriochlorophyll 
derivatives, for example a water-soluble derivative (TOOKAD® Soluble) which is distributed 
primarily in the vasculature at the time of treatment [44]. Its application, which results in 
vascular occlusion following PDT has so far been limited clinically to use in the treatment of 
prostate cancer. TOOKAD® Soluble may be of benefit in the treatment of large breast 
tumours but this has not yet been investigated. In order to improve PDT selectivity and 
minimize destruction of normal breast tissue, various new strategies have been developed 
which target specific characteristics unique to the tumour and its vasculature. It had been 
established that selective tumour receptor tissue factor (TF)-expression is observed in 
almost all breast cancer tissues and that there is an association between the concentration 
of plasma TF and TF-expression in cancer tissues [45].  
Ligand-targeted photodynamic therapy (tPDT) by conjugating factor VII (fVII) protein with 
photosensitiser, verteporfin has been investigated, in order to overcome the poor selectivity 
and enhance the effect of non-targeted PDT for cancer treatment [46]. The results show 
that this method of targeted PDT could selectively kill TF expressing breast cancer cells with 
no side effects in cells which did not express TF. It also resulted in improved effectiveness of 
PDT with greater degree of apoptosis and necrosis and inhibition of tumour growth in mice.  
Tumour cell targeting factor VII Targeted Sn(IV) chlorin e6 (SnCe6) PDT produced 
comparable results [47]. However there has not yet been a further extension of this 
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technique into a phase I clinical trial so far but represents the future for selective tumour 
treatment with PDT. 
 
Mechanisms of PDT-induced Immune response 
Cellular cytotoxicity mechanisms 
Direct cytotoxic effects of PDT cause oxidative stress in the endoplasmic reticulum and 
photo-oxidative damage to cells resulting in apoptosis and tumour necrosis [48][49][50].  
Extra-cellular release of intra-cellular proteins, known as damage-associated molecular 
patterns (DAMPs) typically occurs 1-4 hours after PDT [48]. Various DAMPs have been 
identified. Heat shock proteins (HSPs), calreticulin and high mobility group box -1 (HMGB1) 
are examples of DAMPS, released/expressed by dead and dying cells and potentiate 
immune cell activation, migration to the site of cellular damage and phagocytosis of 
damaged cells which ultimately leads to antigen presentation and T cell activation (Fig 5) 
[48]. PDT related oxidative stress results in activation of transcription factors, such as 
nuclear factor kB and activator protein 1 [51,52].  
 
PDT results in an acute inflammatory response mediated by neutrophils, macrophages and 
other cellular components, which migrate to the treated tumour site [48,53]. Neutrophil 
populations are first to increase and this is facilitated by TNF-a a byproduct of PDT [48,54].  
In addition, immediately post PDT, myloid cells, monocytes, macrophages and mast cell 
population, are also observed to rise [54]. The end result of this process is the activation of 
CD8+ T cells (Fig.5) [8].  
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While neutrophils are the first to increase in number and migrate in response to PDT 
macrophages also have a significant role in potentiating the immune mediated effects and 
are sensitive to changes to PDT dose. Macrophages appear to be preferentially activated by 
low dose PDT. Following PDT, macrophages secrete lysophosphatidylcholine. This protein is 
a substrate in a T and B cell enzymatic pathway that ultimately leads to the production of 
Macrophage Activation factor (MAF), and the resulting activated macrophages elicit tumour 
specific cytotoxic activity [48]. Furthermore PDT appears to enhance the phagocytic activity 
of macrophages facilitating their role in removal of dead and dying cells from the treatment 
site [49]. 
 
T cell mediated anti-tumour activity is central to the efficacy of PDT in both the innate and 
adaptive responses [55,56,57]. Antigen presentation by neutrophils, macrophages and 
dendritic cells to the T cell receptor via MHC class I protein results in CD8+ (cytotoxic) T cell 
activation and tumour specific cytotoxicity. Alternatively MHC class II antigen presentation 
by APCs results in CD4+ (helper) T cell activation (Fig.5). Further dichotomy in T cell activity 
is demonstrated with CD4+ T helper 1 cells responsible for activation of CD8+ cytotoxic T 
cells while CD4+ helper 2 cells causes B cells proliferation and antibody class switching and 
activates macrophages [50].   
 
Cytokine and complement derived cytotoxic mechanisms 
PDT effects the complement system and cytokine production. [48,58,59]. Following PDT 
pro-inflammatory cytokines levels are increased. C3 and C5a promotes neutrophila after 
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PDT. IL-6 is produced in large amounts and promotes megakaryotes and haemopoietic 
progentitor cells production and T cell proliferation (Fig.5) [48,56,60]. However not all 
cytokine activation promotes its pro-inflammatory, anti-tumour activity of PDT but excess 
production results in reduced efficacy in some tumours.  
 
Factors effecting PDT efficacy 
Efficacy depends on the anatomical site [61], the type of photosensitiser and dose [48,62]. 
In addition the treatment conditions, specifically low power density or fluence rates causing 
less oxygen depletion [63] may result in improved immune activation. A normal functioning 
host immune system is a pre-requisite with immune-suppression reducing the success of 
treatment  [48,49,50,64]. Reduced efficacy of anti-tumour activity may be related several 
mechanisms.  PDT mediated immune suppression occurs to counter auto- immune reactions 
[48,50,64].  PDT induced production of VEGF delays DC maturation, lead to T regulatory cell 
(Treg cell) mediated immune suppression. 
 
Low levels of nitric oxide (NO) are produced by tumour cells by via nitric oxide synthetase 
(NOS) in response to PDT, as a cytoprotective defence. This appears, to reduce the efficacy 
of PDT [65]. Conversely Cox inhibitors, which block NO production improve PDT efficacy 
[65,66,67]. Furthermore Nf Kb is also implicated in the regulation of COX-2 expression, 
important in PGE2 and leukotriene production. Selective COX-2 inhibition results in 
improved PDT efficacy by reducing negative feedback regulation of this pathway. 
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PDT in combination immune modulatory agents 
PDT mediated immune response, which extends to distant sites after local treatment appear 
to dependent on multiple factors not all of which are known, and does not occur in all cases 
[56,68]. However studies which combined PDT with an immune- stimulatory agents, have 
demonstrated local and distant immune responses consistently [55,70].  
 Evidence has been presented that PDT combined with immune-modulatory agents can 
induce a sustained immune response and improve efficacy in tumour cell destruction and 
stasis in tumour growth in a number of cancer mouse models including breast cancer. 
[55,70,71,72,73]. Combination treatment caused an increased neutrophil infiltration, 
improvement in tumor antigen presentation, greater T-cell activation, suppressed 
expression of (Tregs) with effective rejection of tumor re-challenge [50]. In some cases this 
was independent of the choice of photosensitiser [50,71]. Recently Xia et al [72] 
demonstrated that a combination of PDT and immunomodulatory agent, CpG 
oligodeoxynucleotide, resulted in delay in metastatic spread, prolonged survival and 
increased activation of CD8+ T cells. Another treatment strategy used by Shams et al [73] is 
a two step treatment process in combination with immune enhancement, with low PDT 
dose (immunogenic) administered followed by high dose with variable anti-tumour efficacy 
in different tumour cell lines. [73]. This treatment prolonged survival and delay in metastatic 
spread. So Far these findings have yet to be translated into the clinical setting. 
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Adjuvant PDT 
Alternative avenues of PDT treatment are also being explored through cell lines and animal 
models. Specifically its role combined with adjuvant radiotherapy and chemotherapy for the 
treatment of breast cancer and its sequelae. Photosensitisers have the potential of acting as 
agents for combination therapy with chemotherapy or radiotherapy. Some photosensitisers 
have been found to be useful as radiosensitisers, with preliminary data suggesting that they 
could be used in the treatment of metastases in some cancers [11,74], but have not been 
used in the treatment of breast cancer so far. However the concept of using PDT as an 
adjuvant to conventional radiotherapy in breast cancer treatment continues to be of 
interest. The effects of combined treatment with radiotherapy and PDT on breast cancer 
cell lines have been investigated using indocyanine green as the photosensitiser and a low 
dose of radiotherapy (4Gy) with encouraging results [75]. PDT effects on normal bone in 
vivo have been studied [76] previously and showed that normal healthy bone is very 
resistant to PDT effects in contrast to radiotherapy so inadvertent light exposure to bone is 
unlikely to cause necrosis.  
 
PDT in combination with radiotherapy to treat bone metastases from breast cancer in an 
animal model has been studied recently [77]. Following radiotherapy alone the established 
spinal metastases were successfully eliminated. However rats also subjected to PDT in 
combination with radiotherapy also showed some evidence of improved trabecular 
structure.  Quantitative histological examination suggested that PDT induced increases to 
bone to marrow ratio mainly due to the increased formation of newly formed woven bone 
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and an increase in osteiod formation compared to rats treated with radiotherapy alone [77]. 
The authors concluded that while they were unable assess if PDT eliminated tumour cells in 
spinal metastases the process of induced tissue injury resulted in an inflammatory response 
as a part of healing. A further beneficial side effect was that the PDT treated areas showed 
reduced amounts of osteoclasts. Since radiotherapy usually causes an increase in 
osteoclasts and bone resorption, adjuvant treatment would reduce this potentially harmful 
effect of radiotherapy. The less desirable effects of combined therapy was that the cortical 
shell thickness of combined treatment areas were significantly thinner, but this did not 
translate into observable measures of mechanical bone weakness; in fact bone-mineral 
density and bone volume was increased [76]. Crucially this study could not establish that 
PDT in an adjuvant setting with radiotherapy improved the outcome of treatment for spinal 
metastases in the short term. However in the long term some of the changes induced by 
PDT may have resulted in improved recovery from treatment. Subsequently the same group 
recently published their findings after evaluation of rat vertebrae 6 weeks after being 
treated with PDT [77]. This randomised study demonstrated that PDT appeared to improve 
vertebral integrity in combination with bisphosphonates or radiotherapy suggesting its 
potential use in adjuvant treatment of spinal metastases [78]. Translation of this work into 
the clinical setting for breast cancer is awaited. 
  
In the setting of adjuvant chemotherapy, PDT also has potential applications. 
Photosensitisers can be used in combination with chemotheraputic agents by 
photochemical internalisation (PCI) [79-81]. Macromolecular chemotheraputic agents, 
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which are subject to endolysosomal sequestration, can be released into the cytosol by this 
method by activation of the photosensitiser which is localised in endolysosomal membranes 
owing to their amphiphilic properties. This allows selective targeting of tumour cells since 
release of the endocytosed agents to their intended intracellular targets occurs within the 
illuminated area [79]. This is another area that requires clinical research to validate its use in 
breast cancer. 
PDT compared to other treatment modalities 
A full discussion of all new technologies emerging of the treatment of breast cancer in 
comparison to PDT is beyond the remit of this review. However there are a few treatments, 
which have been considered as future breast cancer treatments. High intensity focused 
ultrasound (HIFU) and Radio frequency ablation (RFA) are two of the most promising rivals 
to PDT. HIFU relies on the same technical principles as conventional ultrasound, however 
unlike diagnostic ultrasound, HIFU the intensity of HIFU in the focal region is several orders 
higher [82]. HIFU induces coagulative necrosis caused by heat with giant cell reaction with 
chronic inflammation the surrounding normal fatty tissue frequently shows histological 
signs of fat necrosis.  HIFU is associated with an immune response resulting in apoptosis. In 
vitro studies show increases in heat shock protein HSP70, rise in circulating T lymphocytes 
but in contrast to PDT there is greater ratio of CD4+ to CD8+ T cells. So far there have been 
two clinical studies assessing its efficacy in breast cancer [83,84]; although HIFU had 5 year 
disease free survival of 95%, both studies were small with less than 50 patients in total. Long 
term effects of HIFU are unknown, 2 patients in the studies had skin burns and the inability 
to assess margins by histopathology is a significant limitation compared to standard 
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treatment. In addition in contrast to PDT no evidence has been presented that it results in a 
sustained adoptive immune response. Radio frequency ablation (RFA) uses a radiofrequency 
electrode combined with CT or ultrasound to heat and coagulate tissue [85].  Immune 
response related to RFA has been studied, and serum levels of pro-inflammatory cytokines 
were either increased or unchanged with modest transient changes [86,87].  In vivo murine 
studies have shown that there is increase expression of HSP, T cell activation with 
proliferation of CD4+ and CD8+ populations and tumour specific antibodies [86]. 
Furthermore adaptive transfer has been demonstrated in vivo as in PDT [88]. A review of 25 
clinical studies consisting of 400 patients using RFA to treat breast cancer has been 
performed and have shown high efficacy [85]. However their results are difficult to interpret 
due to their heterogeneous inclusion criteria and use of RFA as primary or secondary 
procedure. Burns were significant major complications occurring in a small number of 
patients in the majority of these studies [85].  Finally while there has been no formal 
comparison of conventional primary treatments (surgery, chemotherapy, radiotherapy or 
endocrine therapy) to PDT so far. However in 2014 Spratt et al [89], published a meta-
analysis of treatments for cutaneous metastases almost all from melanoma and breast 
cancer.  This included PDT treatment and the results for objective response showed 
equivalence with radiotherapy.  
 
 PDT and clinical applications in breast cancer treatment    
The first clinical application for this technology in breast cancer treatment was in the 
treatment of skin metastases in chest wall recurrence [90- 94]. 
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The initial series of 37 patients with breast carcinoma chest wall recurrence treated with 
PDT by Khan et al in 1993 [93] (Table 1) showed that this was an effective treatment in 
selected patients although there was a variation in the extent of response. Photofrin was 
used as the photosensitiser in this light dose escalation study to determine the minimal light 
dose at which there was an effective response.  The results showed that 5 patients achieved 
a complete response, 13 demonstrated partial responses and 19 showed no benefit [93]. 
The extent and type, of recurrent disease, were strong determinants of the likelihood of 
response. Minimal and nodular disease responded well to PDT; partial responses were seen 
in patients with disease of moderate extent. A phase I study evaluating mono-L-aspartyl 
chlorin e6 (Npe6).  In a dose escalation study was conducted by Taber et al [91], while there 
were no systemic adverse effects, all patients experienced transient generalised skin 
photosensitivity and light treatment caused immediate tissue blanching indicating vascular 
shutdown [91]. Marked necrosis of the tumor mass was observed and regression of tumor 
occurred between 1-2 days post treatment with formation of an eschar over the tumour 
site.  However re-epithelialisation occurred under the eschar and complete healing occurred 
in 8-12 weeks. The study was also not selective for breast cancer recurrence as only 4 of the 
11 patients in the study having cutaneous breast metastases. The authors found that 
although tumour regression occurred 1 out of 3 patients its effect was incomplete. Tumour 
re-growth occurred on the edges at the interphase between tumour and normal skin. the 
optimum dose to control tumour re-growth was between 2.5 or 3.5 mg/kg combined with 
100 J/cm2 of light energy with 6 of 9 of sites which showed complete response, remaining 
tumor-free through 12 weeks observation [91].  
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Wyss et al treated breast cancer chest wall recurrence in 7 patients with complete response 
[94]. In this short series the photosensitizer meta-tetra (hydroxyphenyl) chlorin (m-THPC), 
was injected intravenously. Response to treatment did not differ when using the 2 different 
drug dose protocols. Healing time depended mainly on the size of the illumination field but 
not on the light dose. Similarly Cuenca et al found that PDT was an effective treatment for 
the palliation of chest wall recurrence using Photofrin [92]. 500 separate cutaneous truncal 
lesions were treated in 14 patients [92]. The follow up period ranged from 6 to 24 months. 
While all patients demonstrated tumour necrosis and 9 out of 14 had complete responses 
and several had regression of untreated lesions there was no effect on disease progression. 
Li et al in 2011 combined PDT with immune therapy with a trial assessing safety and efficacy 
of laser immunotherapy (LIT) for the treatment of metastatic breast cancer[95]. All 10 
patients who were enrolled had either stage 3-4 disease and 8 patients were suitable for 
final evaluation [95].  Only 1 patient had complete response; 4 patients had partial 
response, 2 maintained stable disease and 2 patients with disease progression [95]. There 
was transient thermal injury, whose prolonged duration was strongly associated with 
previous radiotherapy. However there were no serious adverse effects or deaths due to this 
treatment. While the application of immunotherapy to treat cancers is not new this study 
demonstrated that adjuvant treatment with immunotherapy following PDT may improve its 
effectiveness and represents a viable future treatment of tumours at distant sites. Finally 
the first phase I/IIa clinical trial of PDT in the treatment of primary breast cancer is 
underway in the UK (see table 1) with preliminary results expected at the end of 2016 
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(unpublished comunication). If this trial is successful and the treatment is well tolerated this 
will open the door to much needed clinical investigation in PDT. 
 
Discussion 
PDT in breast cancer is still at preliminary stages of research. However, its low toxicity, 
repeatability and potential immunological effects suggest it to be suitable as a treatment 
modality for breast cancer. Translating the advances made in understanding the effects of 
PDT in the cell line based studies and animal models into clinical practice, is the current 
challenge for this treatment. Current conventional breast cancer treatment options are 
successful and set a high bar for novel treatment strategies which need to offer at least 
equal efficacy if not show additional advantages to be accepted as suitable treatment.  The 
scientifIc evidence is mounting in favour of PDT as such a treatment modality. However so 
far, it has only been used as trial treatment of cutaneous metastasis in patients with 
advanced disease. The next uncharted territory is whether treatment of the primary breast 
cancer with PDT might result in a more effective treatment strategy. This is particularly 
pertinent as investigations into the immunomodulatory effects of PDT suggest at least in 
animal models that it stimulates the host immune system to facilitate tumour cell death and 
prevent tumour growth and spread [48,49,50] . Further clinical research may perhaps lead 
to PDT being considered as a method of vaccination against tumours [96]. This clearly would 
be of great advantage as PDT treatment in patients treated for primary breast cancer could 
also result in acquired immunity against the cancer at distant sites for all metastases of the 
same tumour clone. Under these circumstances, its current position as a potential 
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complimentary adjuvant therapy could be extended to become a standard of care in breast 
cancer treatment. Further research is required if PDT is to be used successfully in primary 
breast cancer. 
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TABLE 1: Photosensitisers (PS) investigated for use in breast cancer treatment  
PS Wave 
Length 
(nm) 
Time to PDT 
After  
Dose 
Delivery 
Study Properties/uses/delivery [64] 
Zinc  
phthalo- 
cyannine 
 
675 12 hours In- vitro 
Study on murine 
breast cancer cell 
lines  [29] 
 
2ND generation PS 
Liposomal preparation 
administered intravenously. 
Insoluble in water. 
Not currently used in clinical 
trials 
SnEt2 
-Purlytin 
 
 
660 24 hours Clinical use for 
Treatment of skin 
metastases 
including breast 
cancer 
[33] 
 
2ND generation PS. 
Intravenous adminstration 
Used in Phase II clinical trials 
Localized in skin. Used in 
clinical treatment. 7-14 days 
post administration Photo- 
sensitivity can occur. 
Motexafin 
lutetium 
(Lutex) 
 
720 3-24 hours Clinical use for 
Treatment of skin 
metastases 
including breast 
cancer 
[31] 
2ND generation PS 
water soluble agent 
intravenous administration. 
Used in phase I clinical trial 
for prostate cancer and 
treatment of psoriasis. Low 
incidence of photosensitivity 
Photofrin  
 
 
630 48 hours Clinical Trial for the 
treatment of breast 
cancer skin 
metastases [93] 
 
1st generation PS derivative 
lipophilic agent. Intravenous 
administration.  4-12 weeks 
Risk of Photosensitivity.  
mono-L-
aspartyl 
chlorin 
 
664-667 4 hours Clinical trial for the 
treatment of breast 
cancer skin 
metastases [91] 
 
2nd generation PS derivative 
intravenous administration. 
Soluble in sodium chloride 
solution. Photosensitivity risk 
for up to 3 weeks. 
meta-tetra 
(hydroxyphe
nyl) chlorin 
(m-THPC) 
(Foscan) 
 
652 48-96 hours Patient series 
treatment of breast 
cancer metastases 
[92] 
2ND generation PS  
insoluble in aqueous solution. 
Intravenous administration. 
Used in treatment of head 
and neck, squamous cell 
carcinoma and lung cancers.2-
6 weeks photosensitivity risk.  
Verteporfin 
(Visudyne) 
 
690 1 hour Clinical Trial for 
treatment in 
primary breast 
cancer* used in 
murine breast 
cancer models 
[23,31,32] 
2ND generation PS 
Liposomal preparation.  
Intravenous administration 
Licensed for treatment of 
macular degeneration. Low 
incidence of photosensitivity 
* Trial ongoing at Royal Free London NHS foundation trust since 2013 trial outcome due end of 2016 
(unpublished communication). 
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FIGURE 1 
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FIGURE 2 : The photochemical reactions resulting from PDT (Jablonski diagram) 
The absorption of a photon of light by the photosensitiser leads to a photochemical reaction 
that elevates this photosensitizer molecule from its ground state (S0) to an excited state (S1). 
Subsequently the transition of the photosensitser from the singlet S1 state to the triplet T1 
excitable state allows the photosensitiser to transfer this energy to an oxygen molecule 
transforming it to either reactive oxygen species (type I reaction) its highly reactive singlet 
state (type II reaction).  
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FIGURE 3:  
PDT is usually applied at wavelengths of 600-800nm [29,30]. Across this range the major 
components of living tissue- water, haemoglobin in blood and protein has low absorption of 
light allowing its passage through them with minimal scatter. Shown below is the absorption 
spectrum for PDT which shows this range. 
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FIGURE 4: Shows the relative penetration of light at different wavelengths with blue light 
being the least able to penetrate tissues while infra-red light  is best for tissue penetration 
at depth. 
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